Compare Quest Diagnostics Inc (DGX) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Kaltura Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Kaltura Inc trades at $1.27 (market cap $190.22M). The key difference: Quest Diagnostics Inc is far larger — about 119.9× Kaltura Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals.
| DGX | KLTR | |
|---|---|---|
Market Cap | $22.80B | $190.22M |
Sector | Health | Technology |
52-Week High | $216.02 | $1.97 |
52-Week Low | $166.42 | $1.08 |
Enterprise Value | $28.82B | $172.94M |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
KLTR trades at $1.29, up 0.78% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $180M and narrowing losses, while maintaining a high gross margin of 71.17%. Recent news highlights industry recognition and AI product launches, though cash flow remains negative and equity is thin at $24.39M.
Outlook is mixed: analyst consensus leans buy (44%) with improving profit trends, but high P/B of 41.6 and negative ROE pose valuation risks. Key catalysts include Q2 2026 results on August 5, 2026, while competitive pressure and reliance on AI adoption present ongoing challenges for sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
